# Eastman Chemical Co: overview

EMN · NYSE · CIK 915389 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/emn.md) · [Financials](/companies/emn/financials.md) · [Filings](/companies/emn/filings.md) · [Insiders](/companies/emn/insiders.md)

Latest reported revenue: [$2.51bn](/filings/0000915389-26-000141.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:Revenues, accession 0000915389-26-000141).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,464](/filings/0000915389-25-000183.md) | [2,245 d](/filings/0000915389-26-000013.md) | [2,290](/filings/0000915389-26-000099.md) | [2,287](/filings/0000915389-26-000141.md) | [2,202](/filings/0000915389-25-000183.md) | [1,973 d](/filings/0000915389-26-000013.md) | [2,177](/filings/0000915389-26-000099.md) | [2,513](/filings/0000915389-26-000141.md) |
| Gross margin | % | [24.6%](/filings/0000915389-25-000183.md) | [24.7% d](/filings/0000915389-26-000013.md) | [24.8%](/filings/0000915389-26-000099.md) | [22.1%](/filings/0000915389-26-000141.md) | [19.7%](/filings/0000915389-25-000183.md) | [17.1% d](/filings/0000915389-26-000013.md) | [19.8%](/filings/0000915389-26-000099.md) | [22.3%](/filings/0000915389-26-000141.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [7.3%](/filings/0000915389-25-000183.md) | [14.7% d](/filings/0000915389-26-000013.md) | [7.9%](/filings/0000915389-26-000099.md) | [6.1%](/filings/0000915389-26-000141.md) | [2.1%](/filings/0000915389-25-000183.md) | [5.3% d](/filings/0000915389-26-000013.md) | [4.9%](/filings/0000915389-26-000099.md) | [7.3%](/filings/0000915389-26-000141.md) |
| Diluted EPS | $ per share | [1.53](/filings/0000915389-25-000183.md) | not reported | [1.57](/filings/0000915389-26-000099.md) | [1.20](/filings/0000915389-26-000141.md) | [0.40](/filings/0000915389-25-000183.md) | not reported | [0.93](/filings/0000915389-26-000099.md) | [1.59](/filings/0000915389-26-000141.md) |
| Free cash flow | $m | [276 d](/filings/0000915389-25-000183.md) | [361 d](/filings/0000915389-26-000013.md) | [(314)](/filings/0000915389-26-000099.md) | [83.0 d](/filings/0000915389-26-000141.md) | [265 d](/filings/0000915389-25-000183.md) | [390 d](/filings/0000915389-26-000013.md) | [(240)](/filings/0000915389-26-000099.md) | [124 d](/filings/0000915389-26-000141.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [10.5](/filings/0000915389-24-000016.md) | [10.6](/filings/0000915389-25-000012.md) | [9.2](/filings/0000915389-26-000013.md) | [9.4](/filings/0000915389-26-000013.md) | [8.8](/filings/0000915389-26-000013.md) |
| Gross margin | % | [23.9%](/filings/0000915389-24-000016.md) | [20.2%](/filings/0000915389-25-000012.md) | [22.4%](/filings/0000915389-26-000013.md) | [24.4%](/filings/0000915389-26-000013.md) | [21.1%](/filings/0000915389-26-000013.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [8.2%](/filings/0000915389-24-000016.md) | [7.5%](/filings/0000915389-25-000012.md) | [9.7%](/filings/0000915389-26-000013.md) | [9.6%](/filings/0000915389-26-000013.md) | [5.4%](/filings/0000915389-26-000013.md) |
| Diluted EPS | $ per share | [6.25](/filings/0000915389-24-000016.md) | [6.35](/filings/0000915389-25-000012.md) | [7.49](/filings/0000915389-26-000013.md) | [7.67](/filings/0000915389-26-000013.md) | [4.10](/filings/0000915389-26-000013.md) |
| Free cash flow | $bn | [1.1](/filings/0000915389-24-000016.md) | [0.4](/filings/0000915389-25-000012.md) | [0.5](/filings/0000915389-26-000013.md) | [0.7](/filings/0000915389-26-000013.md) | [0.4](/filings/0000915389-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/emn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.13bn | 16,936,709 |  | Added +445,463 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $506.0m | 7,553,898 |  | Reduced −74,456 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $345.9m | 5,163,630 |  | Added +226,841 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $345.6m | 5,160,164 |  | Added +51,446 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $282.7m | 4,169,105 |  | Added +29,010 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $223.1m | 3,330,732 |  | Added +252,892 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $192.4m | 2,872,422 |  | Reduced −1,035,679 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $178.4m | 2,664,222 |  | Added +52,235 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $165.4m | 2,469,976 |  | Added +225,905 |
| [EARNEST PARTNERS LLC](/funds/1102578.md) | 2026-06-30 | $160.9m | 2,402,860 |  | Reduced −43,374 |

## Recent filings

[All 1,809 filings](/companies/emn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 11:18 ET | [10-Q](/filings/0000915389-26-000172.md) | Quarterly report, period 2026-09-30 | 0000915389-26-000172 |
| 2026-10-29 | 16:19 ET | [8-K](/filings/0000915389-26-000167.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000915389-26-000167 |
| 2026-10-20 | 16:10 ET | [8-K](/filings/0000915389-26-000161.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0000915389-26-000161 |
| 2026-07-31 | 11:10 ET | [10-Q](/filings/0000915389-26-000141.md) | Quarterly report, period 2026-06-30 | 0000915389-26-000141 |
| 2026-07-30 | 16:17 ET | [8-K](/filings/0000915389-26-000138.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000915389-26-000138 |
| 2026-05-12 | 16:05 ET | [8-K](/filings/0000915389-26-000123.md) | 5.07 Shareholder vote results | 0000915389-26-000123 |
| 2026-05-01 | 11:58 ET | [10-Q](/filings/0000915389-26-000099.md) | Quarterly report, period 2026-03-31 | 0000915389-26-000099 |
| 2026-04-30 | 16:17 ET | [8-K](/filings/0000915389-26-000094.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000915389-26-000094 |
| 2026-03-24 | 16:03 ET | [DEF 14A](/filings/0000915389-26-000074.md) | Proxy statement, period 2025-12-31 | 0000915389-26-000074 |
| 2026-02-20 | 16:10 ET | [8-K](/filings/0001193125-26-061351.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-061351 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000915389-26-000013.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5de518a7-c543-401c-8451-80cf81bdd84a)

## About the filer

- CIK: 915389
- Tickers: EMN
- Exchange: NYSE
- SIC code: 2821 Plastic Materials, Synth Resins & Nonvulcan Elastomers
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:19 ET. No prices; not investment advice.